

Thailand with respect to three like product categories classified under 12 Harmonized Tariff Schedule (HTS) item numbers.

EFFECTIVE DATE: April 25, 1995.

FOR FURTHER INFORMATION CONTACT:

Jacqueline Wallace or Steve Presing, Office of Agreements Compliance, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482-1394 or (202) 482-0194.

SUPPLEMENTARY INFORMATION:

Background

On March 1, 1994, the Department published in the **Federal Register** notification of its intent to terminate the suspended investigation covering Certain Textile Mill Products from Thailand and invited interested parties to comment (59 FR 9727, dated March 1, 1994). On March 31, 1994, the Department received timely objections to the intent to terminate the suspended investigation from the Amalgamated Clothing and Textile Workers Union (ACTWU); American Textile Manufacturers Institute, Inc. (ATMI); Certain Individual Producers of ATMI; American Yarn Spinners Association (AYSA); and Certain Individual Producers of AYSA.

On April 22, 1994, the Royal Thai Government (RTG) and Thai Textile Manufacturers Association (TTMA), challenged the interested party status of those parties who objected to our intent to terminate the suspended investigation. As a result of the objections received from the RTG and TTMA, the Department requested certifications demonstrating interested party status from ACTWU, ATMI, AYSA, and certain individual producers of AYSA in accordance with 19 CFR 355.2(i) (3), (4), and (5). Based on our analysis of interested party status by like product categories (*See internal recommendation from Roland MacDonald to Joseph A. Spetrini* dated January 12, 1995, for a complete analysis), we have determined that it is appropriate to terminate the suspended investigation with respect to the following three like product categories because the Department did not receive certifications demonstrating interested party status:

(1) Yarn of Man Made Fiber
Continuous Cellulosic
5401.20.0000
5406.20.0000

(2) Other Miscellaneous Categories

Wadding & Articles

5601.10.1000
5601.21.0010
5601.21.0090

Other Made-up Articles

6307.10.2005
6307.10.2015
6307.10.2020
6307.10.2027
6307.10.2028
6307.10.2030

(3) Wool Made-Ups and Miscellaneous

Floor Coverings
5703.10.0000

This notice is in accordance with 19 CFR 355.25(d)(4)(i).

Dated: April 18, 1995.

Joseph A. Spetrini,

Deputy Assistant Secretary for Compliance.

[FR Doc. 95-10166 Filed 4-24-95; 8:45 am]

BILLING CODE 3510-DS-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patents Concerning Anticonvulsant and Neuroprotective Agents

AGENCY: U.S. Army Medical Research and Materiel Command, Department of the Army, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 5,258,386 entitled "(+)-3-Substituted-N-Alkylmorphinans, Synthesis and use as Anticonvulsant and Neuroprotective Agents" and issued on November 1, 1993, and U.S. Patent No. 5,331,010 entitled "1-Phenylalkanecarboxylic Acid Derivatives as Anticonvulsant and Neuroprotective Agents; and issued on July 19, 1994. These patents have been assigned to the United States Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney, (301) 619-2065 or telefax (301) 619-7714.

SUPPLEMENTARY INFORMATION: The inventions represent discoveries that members of certain classes of compounds [(+)-3-substituted-N-

alkylmorphinans and 1-phenylalkanecarboxylic acids] possess effective usefulness as nonaddictive anticonvulsant and neuroprotective agents. The 1-phenylalkanecarboxylic acids include novel non-opiate derivatives as well as previously published species. Methods for controlling convulsions in a variety of pharmaceutical formulations and modalities are described. In both inventions, novel compounds which possess these biological properties are presented in a method or methods of use for preventing, treating, or controlling convulsions in mammals having a need for such treatment. The compounds do not lead to dependency, have low toxicity, and provide effective anticonvulsant or neuroprotective treatment with little or no behavioral detriment to the recipient.

Gregory D. Showalter,

Army Federal Register Liaison Officer.

[FR Doc. 95-10079 Filed 4-24-95; 8:45 am]

BILLING CODE 3710-08-M

Availability of Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning a Method for Lysing Thrombi

AGENCY: U.S. Army Medical Research and Materiel Command, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 5,399,158, entitled "Method of Lysing Thrombi", and issued on March 21, 1995. This patent has been assigned to the United States Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, Fort Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: Mr. John F. Moran, Patent Attorney, (301) 619-2065 or telefax (301) 619-7714.

SUPPLEMENTARY INFORMATION: The invention describes an improved method for prevention or treatment of thrombosis, including deep venous thrombosis (DVT) and acute arterial thrombosis, such as coronary artery thrombosis, while avoiding damage to the surrounding tissue. The method includes the administration of plasminogen activators in conjunction with intermittent (pulse mode) ultrasound and the imposition of a fluid-containing barrier between the